.............. da das Geld nun bis zum 3. Quartal 2023 reicht, sollte dies möglich sein
Dennoch stellt die Ausgabe der Aktien zum Preis von 1.05 $ an die bisherigen Großaktionäre eine Art "Geschenk" dar.
"Amid the company's product pipeline, treatment with FLT180a for male adult patients with hemophilia B has significant potential to achieve a functional cure. That means the company could soon transition from a clinical-stage developer to a drugmaker and start reporting sales, which could take its stock price to much higher levels than it is now.
Given the encouraging results of previous trials in which FLT180a demonstrated a significant reduction of symptoms while being generally well tolerated by patients, this product of Freeline Therapeutic is on track to move into the pivotal phase 3 trial in less than a year. Thus, it could get FDA approval ahead of expectations. In the meantime, any progress in the FLT180a pipeline could trigger a significant uptrend in the stock price."
Deutschland schafft sich selbst ab.
Traurig aber wahr.